Showing results (81-90 of 88) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Journal of Hematology & Oncology|January 12, 2019
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysisNarendranath Epperla, Kwang W Ahn, Carlos Litovich, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2017
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid LeukemiaKenneth F Bradstock, Emma Link, Juliana Di Iulio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 TrialJustin Ferdinandus, Helen Kaul, Alexander Fosså, et al.Blood Cancer Journal|March 27, 2024
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?Ing Soo Tiong, Meaghan Wall, Ashish Bajel, et al.Cancer|April 13, 2018
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failureSonali M Smith, James Godfrey, Kwang Woo Ahn, et al.Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.Nature Communications|May 13, 2025
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCsJulie A I Thoms, Feng Yan, Henry R Hampton, et al.Blood Advances|July 15, 2020
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR reportZheng Zhou, Rajneesh Nath, Jan Cerny, et al.Pageof 9